Background: In approximately 15% of human cancers, telomere length is maintained independently of telomerase by the homologous recombination (HR)-mediated alternative lengthening of telomeres (ALT) pathway. Whether the ALT pathway can be exploited for therapeutic treatment remains unknown. The purpose of this study is to develop oncotherapeutic agent to target ALT cancers. Methods: Surface plasmon resonance assay, antibody to G-quadruplex, and fluorescence in situ hybridization (FISH) were used to discover Tetra-Pt(bpy), a cisplatin derivative that specifically targets telomeric G-quadruplex. We used immunofluorescence, FISH, C-circle assay, and chromosome orientation FISH to evaluate the inhibitory effect of Tetra-Pt(bpy) on ALT activity in human ALT cancers. The shortening of telomere length induced by Tetra-Pt(bpy) was determined by telomere restriction fragment or Q-FISH. Cell destination after Tetra-Pt(bpy) treatment was determined by b-gal staining or apoptosis assay. Nude mice (n ¼ 4 per group) were injected with U2OS cells to evaluate the effects of Tetra-Pt(bpy) on tumor growth. All statistical tests were two-sided. Results: Tetra-Pt(bpy) inhibits the strand invasion/annealing step of telomeric homologous recombination by selectively converting telomeric ssDNA to a G-quadruplex. ALT-cells treated with Tetra-Pt(bpy) show fewer ALT-associated promyelocytic leukemia bodies (untreated: mean6SD ¼ 5.960.2 vs treated: mean6SD ¼ 3.160.1, P < .001), fewer extrachromosomal C-circles (untreated: mean6SD ¼ 100.561.6 vs treated: mean6SD ¼ 18.061.7, P < .001), and reduced telomere sister chromatin exchanges (untreated: mean6SD ¼ 25.2%61.5% vs treated: mean6SD ¼ 13.1%61.9%, P < .001). Consequently, critically short telomeres accumulate after multiple population doublings (untreated: mean6SD ¼ 18.9%61.7% vs treated: mean6SD ¼ 57.4%62.2%, P < .001), resulting in cell death by apoptosis or senescence. In vivo, Tetra-Pt(bpy) severely inhibits the growth of ALT-cell xenograft tumors in mice (untreated: mean6SD ¼ 57.163.7 mm 3 vs treated: mean6SD ¼ 19.063.2 mm 3 , P < .001).
known as alternative lengthening of telomeres (ALT), which requires the endogenous homologous recombination (HR) machinery (3) . A recent study showed that anticancer therapies that target telomerase may activate ALT as an unintended side effect (4) . Therefore, anticancer therapeutics targeting ALT, although not yet available, would be extremely valuable.
ALT cancer cells are characterized by an elevated frequency of telomere-sister chromatid exchanges (T-SCEs) (5, 6) , the presence of ALT-associated promyelocytic leukemia (PML) nuclear bodies (APBs) (7) , and abundant extrachromosomal circular telomeric DNA (C-circles) (8, 9) . Although the molecular details involved in the ALT mechanism are not yet clear, current mechanistic evidence suggests a model in which the 3'-terminus of single-stranded telomeric DNA invades double-stranded telomeric DNA or anneals to a single-stranded region of extrachromosomal telomeric DNA, allowing templated extension of the invading/annealing ssDNA (10) . In this regard, a reagent that prevents the invasion/annealing of telomeric ssDNA could have potential value as an anti-ALT cancer therapeutic.
Structural studies show that human single-stranded telomeric repeats, TTAGGG, are able to adopt a G-quadruplex structure, which is stabilized by Hoogsteen hydrogen bonding (11) . The G-quadruplex preferentially forms at the furthest 3'-end of telomeric ssDNA (12) , which renders the 3'-terminus inaccessible and may block invasion or annealing during HR-mediated telomere extension. In this context, a ligand capable of specifically stabilizing the telomeric G-quadruplex (T-quadruplex) would be particularly valuable. Considering that G-quadruplex sequences are widely present on genome and that the ligand could result in a variety of cellular consequences including altered gene expression (13) , impaired DNA replication (14) , and/or cell cycle arrest (15) , the search for a G-quadruplex ligand that specifically targets T-quadruplex without causing adverse side effects in normal cells is desired.
Here, we aimed to screen and identify a Pt derivative that specifically binds to T-quadruplex and blocks HR-mediated telomere lengthening in ALT cancer cells with few or no detectable adverse "off-target" effects in human normal cells.
Methods

Cell Culture
U2OS, SAOS2, and MRC5 cells were obtained from Cell Resource Center of Peking Union Medical College and verified by standardized short tandem repeat analysis. Cells were cultured at 37 C under 5% CO 2 in DMEM (Sigma, St. Louis, MO), supplemented with 10% fetal calf serum (PPA-GE, Marlborough, MA) and 100 U/mL penicillin and streptomycin (HyClone-GE, Marlborough, MA).
Surface Plasmon Resonance
Surface plasmon resonance was performed as described previously (16) . Details can be found in the Supplementary Methods (available online).
Fluorescence In Situ Hybridization and Immunofluorescence
Fluorescence in situ hybridization (FISH) and immunofluorescence (IF) were performed as previously described (17) , and details can be found in the Supplementary Methods (available online).
Telomere Quantitative Fluorescence In Situ Hybridization
Quantitative FISH (Q-FISH) was performed as previously described (18) . Cy3-labeled (CCCTAA) 3 PNA probe (Panagene, Daegu, Korea) was used. Fluorescence of telomeres was digitally imaged on a Zeiss microscope with Cy3/DAPI filters. The fluorescence intensity of telomeres was integrated and analyzed using AxioVision software 4.8 and the TFL-TELO program (19) .
Chromosome Orientation Fluorescence In Situ Hybridization Assay
Chromosome orientation FISH (CO-FISH) was performed as previously described (20) . Cy3-labeled (CCCTAA) 3 and FITC-(GGGATT) 3 PNA probes (Panagene) were used. The fluorescence signal was digitally imaged on a Zeiss microscope with Cy3/ FITC /DAPI filters.
Animal Care and Ethics Statement
Four-week-old female BALB/c-nu mice were purchased from the Laboratory Animal Center of Sun Yat-sen University. Mice were housed under temperature-controlled (22 o C 6 1 o C) and light-controlled conditions with free access to food and water in a pathogen-free animal facility. All experimental protocols concerning the handling of mice were approved by the institutional animal care and use committee of Sun Yat-sen University.
Establishment of Xenograft Models Using Human U2OS cells
A total of 1.0 Â 10 6 U2OS cells were inoculated subcutaneously into the dorsal flank of the nude mice in 100 lL phosphate-buffered saline (PBS). Mice were randomly divided into control and Tetra-Pt(bpy) treatment groups (n ¼ 4 per group). Mice were i.p. injected every two days for 40 days (U2OS) at a dose of 20 mg/kg in 100 lL PBS per mouse. No mouse died during the experimental period. The tumors were resected, and their size was estimated from the measurements of the longest diameter across the tumor and the corresponding perpendicular diameter.
Statistical Analysis
The Student's two-tailed unpaired t test was used to determine statistical significance, and a P value of less than .05 was considered statistically significant. Spearman's rank correlation analysis was used to determine a correlation coefficient (R) between the rankings of RNA-seq data from untreated and TetraPt(bpy)-treated cells.
Results
Characterization of Tetra-Pt(bpy) as a Ligand Selectively Stabilizing Telomeric G-Quadruplex
We previously synthesized and screened a library of cisplatin derivatives for the ability to bind with high affinity to the Gquadruplex (21) (22) (23) (24) (25) . We rescreened this library and identified Tetra-Pt(bpy), which is composed of self-assembled Pt(II) molecular squares linked with 4,4'-dipyridyl bridges ( Figure 1A ). We then employed the surface plasmon resonance technique (26) to determine the affinity of Tetra-Pt(bpy) toward the T-quadruplex, the G-quadruplex formed by another sequence, and single-or double-stranded DNA. The K D of Tetra-Pt(bpy) for the T-quadruplex was calculated to be 1.13 Â 10 M) is about six orders of magnitude lower than the affinity for the T-quadruplex ( Figure 1B ). We also found that under near-physiological conditions (crowding and 100 mM K þ ), Tetra-Pt(bpy) induced the formation of a parallel T-quadruplex (a positive peak at 265 nm and negative peak at 238 nm on circular dichroism [CD] spectrometry) ( Figure 1C) . Accordingly, the melting temperature of the T-quadruplex is 24.8 o C higher in the presence of Tetra-Pt(bpy) than in its absence ( Figure 1D ), demonstrating that T-quadruplex is stabilized by Tetra-Pt(bpy).
MTT assay was performed to determine the effect of TetraPt(bpy) on cell viability. The results showed that IC 50 for normal MRC5 cells (89.3 mM) is much greater than that for ALT U2OS (15.8 mM) or SAOS2 cells (14.5 mM) (Supplementary Table 1 , available online), indicating that Tetra-Pt(bpy) is more toxic to ALT cancer than normal cells.
Evaluation of the Ability of Tetra-Pt(bpy) to Inhibit Telomeric HR in ALT Cells
Because Tetra-Pt(bpy) stabilizes the T-quadruplex in vitro, it may promote the formation of G-quadruplex in the telomeric DNA in vivo. To test this, immunofluorescence using antibodies to G-quadruplex (BG4) (27) and FISH were performed to visualize G-quadruplex and telomeres, respectively. In ALT-positive U2OS cells, 48-hour treatment with Tetra-Pt(bpy) (2.0 mM) increased the amount of BG4 foci (eg, G-quadruplex) that colocalized with telomeres (P < .001) (Figure 2A ), with little effect (P ¼ .98) on the total number of BG4 foci in cells ( Figure 2B ), demonstrating that Tetra-Pt(bpy) selectively promotes the formation of T-quadruplex.
HR-dependent ALT is initiated when telomeric ssDNA invades telomeric dsDNA (strand invasion), allowing templated extension of the ssDNA terminus (6,10). To mimic this situation, Figure 1 . Tetra-Pt(bpy) structure and its affinity to telomeric G-quedruplex. A) The molecular structure of Tetra-Pt(bpy). B) Affinity (K D ) of Tetra-Pt(bpy) for the G-quadruplex, dsDNA, and ssDNA determined by surface plasmon resonance. K D was calculated through global fitting of the kinetic data obtained for various concentrations of the compounds using a two-state binding model. Tetra-Pt(bpy) was injected at 62.5, 125, 250, 500, 1000 nM for telomeric G-quadruplex; or 125, 250, 500, 1000, 2000 nM for dsDNA and ssDNA. C) Circular dichroism (CD) spectrometry determination of G-quadruplex induced by Tetra-Pt(bpy). The conformation of G4 (human telomeric G-quadruplex) sequence (3 mM) was determined by CD spectrometry after incubation with Tetra-Pt(bpy) (6 mM) for the indicated times. D) Fluorescence resonance energy transfer thermal melting assay to determine T m of G-quadruplex DNA in the absence or presence of Tetra-Pt(bpy). Spectra were collected sequentially over the temperature range of 37 C to 100 C. 
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we carried out an in vitro experiment to investigate the effect of T-quadruplex formation on strand invasion using telomeric ssDNA (ie, 5' biotin-end-labeled (TTAGGG) 5 oligonucleotides, referred as T-oligo) and a dsDNA plasmid carrying 800 bp of telomeric dsDNA ( Figure 2C ). The formation of T-quadruplex on the T-oligo was confirmed by the CD assay (Supplementary Figure  2A , available online). We found that Tetra-Pt(bpy) inhibited the invasion of plasmid DNA by the T-oligo, reducing the abundance of the slow-migrating biotin-labeled species in a concentration-dependent manner ( Figure 2D ). We then probed for in vivo evidence that strand invasion is inhibited by Tetra-Pt(bpy). Replication protein A (RPA) coated ssDNA is a key intermediate during strand invasion of HR (28, 29) ; the T-quadruplex induced by Tetra-Pt(bpy) may reduce the association of RPA with telomeric ssDNA. To test this, we costained RPA and telomeres in untreated and Tetra-Pt(bpy)-treated U2OS cells. The cells with the knockdown of RPA by siRNA were used as a control ( Figure 2E ; Supplementary Figure  2D Moreover, we also examined the telomeric localization of RAD51, an essential protein that associates with ssDNA and initiates the homologue search for strand pairing/invasion during HR. We observed a decrease in the number of RAD51 foci at telomeres in U2OS cells treated with a varying concentration of TetraPt(bpy) ( To confirm the observations in U2OS, another ALT cancer cell line, SAOS2, was used. We observed that both RPA and RAD51 foci at telomeres decreased in response to Tetra-Pt(bpy) treatment (Supplementary Figure 3 , available online), suggesting that TetraPt(bpy) inhibits strand invasion of telomeric DNA in ALT cells.
As a result of strand invasion inhibition, it is speculated that telomeric HR would be substantially suppressed. HR at telomeres leads to telomere-sister chromatin exchanges (30) . We thus performed CO-FISH to determine the frequency of T-SCEs in control and Tetra-Pt(bpy)-treated U2OS cells. Indeed, TetraPt(bpy)-treated cells showed decreased T-SCEs in a concentration-dependent manner (untreated: mean6SD ¼ 25.2%61.5 vs treated: mean6SD ¼ 13.1%61.9, P < .001) (Figure 2, I and J).
Effect of Tetra-Pt(bpy) on ALT Activity
In addition to the high frequency of HR at telomeres, hallmarks of ALT also include the presence of extrachromosomal C-circle DNA and the formation of ALT-associated PML bodies (APBs). The depletion of RPA or RAD51 by siRNA in U2OS resulted in a decreased number of APBs (Supplementary Figure 2 , E and F, available online), suggesting that HR impairment inhibits ALT activity. Using a previously characterized assay for C-circle DNA (31), we observed less C-circle DNA in Tetra-Pt(bpy)-treated U2OS (untreated: mean6SD ¼ 100.561.6 vs treated: mean6SD ¼ 18.061.7, P < .001) (Figure 3, A and B ) and SAOS2 cells (Supplementary Figure 4, A and B, available online) . The number of APBs also decreased (untreated: The Consequence of Inhibited Telomeric HR and Suppressed ALT Activity by Tetra-Pt(bpy)
We measured the average telomere length in control and TetraPt(bpy)-treated U2OS and SAOS2 cells using the telomere restriction fragment assay. We observed a progressive shortening of telomeres in SAOS2 and U2OS cells in response to Tetra-Pt(bpy) treatment (Supplementary Figure 5 , available online). To accurately determine telomere shortening induced by Tetra-Pt(bpy), we also performed Q-FISH on U2OS cells ( Figure 4A ). Shorter telomeres in Tetra-Pt(bpy)-treated cells (2.0 mM for 13 days) were observed as compared with untreated cells ( Figure 4B ). Moreover, among 3000 metaphase chromosomes from control cells, 18.9% (SD ¼ 1.7%) had at least one "telomere-free end" (telomere with undetectable signal), whereas from cells treated with TetraPt(bpy), 57.4% (SD ¼ 2.2%) of chromosomes had one or more telomere-free ends (P < .001) ( Figure 4C ). This suggests that the treatment with Tetra-Pt(bpy) induces the accumulation of extremely short telomeres in U2OS cells. With an increased time of treatment, the percentage of cells with telomere dysfunctioninduced foci (TIFs; ie, 53BP1 or c-H2AX foci at telomeres) was increased gradually (Supplementary Figure 6 To explore how Tetra-Pt(bpy) affects the growth of human normal cells, we monitored the proliferation of human normal fibroblast MRC5 cells over 24 days (>16 population doublings) and found that Tetra-Pt(bpy) has no (0.5, 1.0 mM) or a very small (2.0 mM) inhibitory effect on the proliferation of cells ( Figure 5E ). To explore a possible effect of Tetra-Pt(bpy) on gene expression, we performed RNA-seq whole-transcriptome sequencing (mRNA, Hisep2000-PE125) of MRC5 and U2OS cells grown in the presence or absence of 2.0 mM Tetra-Pt(bpy). The top 240 mRNA transcripts and their abundance are listed in Supplementary Tables 2 and 3 (available online) , and the sequence data can be found in the GEO database under accession number GSE74029. Tetra-Pt(bpy) (2.0 mM) had no apparent effect on gene expression in both cell lines ( Figure 5F ; Supplementary Figure 9A , available online). This conclusion was confirmed using Spearman's rank correlation analysis, which showed a correlation coefficient (R) of 0.9817 ( Figure 5G ; Supplementary Figure 9B , available online). 
B) Quantification of data in (A). C)
Immunofluorescence and fluorescence in situ hybridization were used to detect the formation of ALT-associated promyelocytic leukemia (PML) bodies in untreated and Tetra-Pt(bpy)-treated cells. Cells were treated with the indicated concentration of Tetra-Pt(bpy) for seven days. Cells treated with 0.01% DMSO were used as a control (control). Antibody to PML and cy3-labeled telomeric probe were used to visualize PML bodies and telomeres, respectively. D) Quantification of (C). For each group, 200 or more cells were examined, and values are the average 6 SD of three independent experiments. The Student's two-tailed unpaired t test was used to determine statistical significance between the control and the sample treated with the indicated concentration of Tetra-Pt(bpy). APB ¼ alternative lengthening of telomeres-associated promyelocytic leukemia bodies; PML ¼ promyelocytic leukemia; Tel ¼ cy3-labeled telomeric probe for hybridization. We next examined the effect of Tetra-Pt(bpy) on telomere length in MRC5 cells. MRC5 cells do not express telomerase, and telomere length decreases with every population doubling (PD) ( Figure 5H ). Using the telomere restriction fragment assay, we found that there is no statistically significant difference (P ¼ .50) in telomere shortening rate between Tetra-Pt(bpy)-treated and untreated MRC5 cells ( Figure 5I ). This suggests that TetraPt(bpy) has little or no impact on telomere maintenance, For each group, 300 or more cells from three independent experiments were examined. P values were calculated using the two-tailed unpaired Student's t test.
Tel ¼ cy3-labeled telomeric probe for hybridization.
ARTICLE X-h. Zheng et al. Figure 10A, available online) . In addition, cisplatin is less efficient than Tetra-Pt(bpy) in suppressing the growth of ALT cancer (U2OS and SAOS2) (Supplementary Figure 10A , available online). Cisplatin treatment resulted in no decrease of APBs and C-circle in U2OS cells, demonstrating that cisplatin has no inhibitory effect on ALT (Supplementary Figure 10 
Discussion
The rationale of our study was based on the notion that singlestranded telomeric DNA can exist as a T-quadruplex in vitro (33) and in vivo (27) . We speculated that ligands that stabilize the Tquadruplex, which is refractory to strand invasion during HR, might inhibit telomere extension in ALT cancer cells. In this regard, the criteria for an ALT-targeted G-quadruplex ligand include a high affinity for the T-quadruplex but a low affinity for the non-telomeric G-quadruplex, dsDNA, and ssDNA, thus having no or low toxicity to normal cells because of off-target effects. Tetra-Pt(bpy) satisfies all of the criteria. While telomeric HR is indispensable for telomere length maintenance of ALT cancers, it rarely occurs in human normal cells. Tetra-Pt(bpy) inhibits HR-mediated telomere lengthening of ALT cancer, thereby triggering DNA damage-induced cell death. Tetra-Pt(bpy) leads to increased formation of the T-quadruplex and a decrease in the number of telomere-localized RPA and RAD51 foci, suggesting a decrease in HR intermediates (34, 35) . Consistently, decreased frequency of T-SCEs and attenuated C-circles/APBs was observed, indicating the suppression of ALT. Consequently, the average telomere length decreased and the number of telomere-free chromosome termini increased in cells treated with Tetra-Pt(bpy), which induce a DNA damage response leading to apoptosis or senescence.
It is the shortest telomere, but not the average telomere length, that is critical for cell viability (36) . In general, telomeres in ALT cancer cells tend to be highly heterogeneous in length, so that some are extremely long while others are extremely short. Because the extremely short telomeres would immediately trigger DDR once the ALT mechanism is inhibited, ALT cancer cells are expected to be very sensitive to agents that inhibit telomeric HR. Consistent with this scenario, U2OS or SAOS2 cells begin to undergo cell proliferation slowdown after only 15 or 10 days of Tetra-Pt(bpy) treatment, respectively. These results suggest that Tetra-Pt(bpy) has the potential to be a fast-acting anticancer agent, able to rapidly inhibit proliferation of ALT cancer cells in vivo.
Cisplatin is one of the most effective and widely used anticancer agents for treating solid tumors that inhibits DNA synthesis and induces DDR in both cancer and normal cells (37) . Therefore, some unwanted effects may be caused by cisplatin. In contrast, Tetra-Pt(bpy) does not form covalent DNA adducts, has a low affinity for dsDNA and ssDNA, and has a very limited effect on the proliferation of normal cells. In this context, TetraPt(bpy) is much safer than cisplatin for cancer therapeutics. This study was limited to well-established ALT cell lines growing in culture or mice. Thus, the applicability of Tetra-Pt(bpy) from this study to PDX models and patients may be questioned. In addition, Tetra-Pt(bpy) might be slower-acting than cisplatin, taking a period of time until cell death is triggered by extremely short telomeres. However, this might be a small trade-off for the high specificity of Tetra-Pt(bpy) for ALT cancer cells, which may reduce the risk of adverse off-target effects in normal human cells.
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